Editor’s Note: Maeleigh Tidd delivers another thought-provoking post in our Pharmaceutical Inequalities series. She reaches back to the 1980s to consider how ACT UP protests led to greater affordability of HIV drugs, and argues that the persisting structural inequalities must be addressed by EHEI.
In 1987, six-years into the rampant spread of the human immunodeficiency virus (HIV) and progression of acquired immunodeficiency syndrome (AIDS) leading to 40,000 deaths in the U.S., the FDA approved the first known antiviral drug for the treatment of AIDS. The approval of AZT (zidovudine) was the first scientific breakthrough in treating, and potentially ending, this “death sentence” of a disease. Yet, as the only treatment option available to the growing number of vulnerable and dying individuals with HIV/AIDS, it was outrageously unaffordable with a price tag of over $10,000 per year.
This drug profiting and the overall poor response to the epidemic at hand, led to the formation of the non-partisan group Aids Coalition to Unleash Power (ACT UP), a group of LGBTQ+ activists ‘united in anger and committed to direct action to end the AIDS crisis’.